CA2075107A1 - Composition pharmaceutique de dehydropyridine avec neuroleptique - Google Patents

Composition pharmaceutique de dehydropyridine avec neuroleptique

Info

Publication number
CA2075107A1
CA2075107A1 CA 2075107 CA2075107A CA2075107A1 CA 2075107 A1 CA2075107 A1 CA 2075107A1 CA 2075107 CA2075107 CA 2075107 CA 2075107 A CA2075107 A CA 2075107A CA 2075107 A1 CA2075107 A1 CA 2075107A1
Authority
CA
Canada
Prior art keywords
neuroleptic
calcium channel
channel blocker
dihydropyridine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2075107
Other languages
English (en)
Inventor
Sherry L. Dilullo
Mathew T. Martin-Iverson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MARTIN IVERSON MATHEW T
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 2075107 priority Critical patent/CA2075107A1/fr
Publication of CA2075107A1 publication Critical patent/CA2075107A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 2075107 1992-07-31 1992-07-31 Composition pharmaceutique de dehydropyridine avec neuroleptique Abandoned CA2075107A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2075107 CA2075107A1 (fr) 1992-07-31 1992-07-31 Composition pharmaceutique de dehydropyridine avec neuroleptique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2075107 CA2075107A1 (fr) 1992-07-31 1992-07-31 Composition pharmaceutique de dehydropyridine avec neuroleptique

Publications (1)

Publication Number Publication Date
CA2075107A1 true CA2075107A1 (fr) 1994-02-01

Family

ID=4150243

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2075107 Abandoned CA2075107A1 (fr) 1992-07-31 1992-07-31 Composition pharmaceutique de dehydropyridine avec neuroleptique

Country Status (1)

Country Link
CA (1) CA2075107A1 (fr)

Similar Documents

Publication Publication Date Title
AU675240B2 (en) Terfenadine metabolites and their optically pure isomers for treating allergic disorders
Maurice et al. SA4503, a novel cognitive enhancer with σ1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice
EP1096932B1 (fr) Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium
US6262049B1 (en) Method of reducing nicotine and tobacco craving in mammals
KR100753984B1 (ko) 우회전성 모르피난의 신경보호적 특성
US5026716A (en) Method of treatment of anxiety and anxio-depressive disorders
AU2005208871B2 (en) Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
RU2746871C2 (ru) Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств
SK287180B6 (sk) Kombinácia účinných látok na medikamentóznu terapiu návykových alebo omamných prostriedkov
US5180729A (en) Use of sigma receptor antagonists for treatment of cocaine abuse
WO1995007690A1 (fr) Composition et procede destines a traiter le besoin de nicotine chez les personnes qui cessent de fumer
US5162341A (en) Use of sigma receptor antagonists for treatment of amphetamine abuse
Tolliver et al. Comparison of cocaine and GBR 12935: effects of locomotor activity and stereotypy in two inbred mouse strains
US6380216B1 (en) Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders
KR20060100443A (ko) 이상지혈증의 예방과 치료, 및 이상지혈증 및(또는) 비만과관련된 질환의 예방과 치료를 위한 약제의 제조에있어서의 피라졸 유도체의 용도
AU1110099A (en) Method of reducing craving in mammals
WO2017015349A1 (fr) Combinaison muscarinique d'un antagoniste sélectif du récepteur m2 et d'un antagoniste non sélectif périphérique pour le traitement de troubles hypocholinergiques
CA2075107A1 (fr) Composition pharmaceutique de dehydropyridine avec neuroleptique
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
AU629688B2 (en) Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists
CN1767833A (zh) 卡马西平衍生物在治疗痴呆患者的激动中的用途
DiLullo et al. Calcium channel blockade interacts with a neuroleptic to attenuate the conditioning of amphetamine's behavioral effects in the rat
US20010016584A1 (en) Treatment of pain
CA2559493A1 (fr) Composition pharmaceutique combinee concue pour inhiber le declin de fonctions cognitives
EP1503765A2 (fr) Utilisation de modulateurs des recepteurs nicotiniques dans le traitement d'un dysfonctionnement cognitif

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead